|
| |
LECTURES
|
Current Trends in Lung and Head & Neck Cancers
March 7, 2008
Atlanta, GA
- Adjuvant Therapy for NSCLC: Where Are We in 2008?
- Combined-Modality Therapy for Stage III NSCLC
- State of the Art in Advanced NSCLC
- What’s New With Angiogenesis Inhibitors in NSCLC?
- Recent Developments With EGFR Inhibition
- Pharmacogenomic Customization of Lung Cancer Therapy
- Novel Agents in Development for NSCLC
- Head and Neck Cancer: Current Clinical Data in 2008
- 2008 Controversies in Head and Neck Cancer
|
|
|
Eighth International Lung Cancer Congress
- Targeting Angiogenesis in First- and Second-line Therapy of Lung Cancer
- Staging
- New Targeted Approaches to Second- and Third-line Therapy of NSCLC
- Screening
- EGFR-Targeted Therapies
- Treatment of Stage III NSCLC
- Treatment of Early-Stage NSCLC
- Personalized Approaches to the Treatment of Lung Cancer
- Cooperative Group Strategies: Roundtable Discussion on First- and Second-line Therapies of Advanced NSCLC and Limited and Extensive SCLC
- Special Populations
- SCLC and Mesothelioma
|
|
|
Emerging Pathways With Therapeutic Potential in Cancer
June 1, 2007
Chicago, IL
- Targeting Signaling Pathways as a Core Strategy for Inhibiting Cancer Cell Growth
- Clinical Development of Agents Targeting the MAP/MEK and PI3K/Akt Pathways: Key Regulators of Proliferation and Survival in Cancer
- Novel Strategies to Inhibit Signaling Through VEGF Receptor in the Treatment of Cancer
- Targeted Immunotherapy for Lung Cancer
- Potential Immunologic Targets in Melanoma
- Combining Targeted Agents in Solid Tumors: Will Horizontal or Vertical Inhibition Improve the Therapeutic Index in Cancer?
|
|
|
| |
PUBLICATIONS
|
 |
Vol. 2, No. 6
1 AMA
PRA Category 1 Credit™
Expiration date: January 17, 2009
- Current Status of Antiangiogenesis Therapy of Colorectal Cancer: Timing and Duration of Therapy
- Combined Modality Therapy in Early-Stage Non–Small-Cell Lung Cancer: The Potential and Future Role of Antiangiogenic Agents
- Targeting the Tumor Microenvironment
|
|
 |
December 2007
1 AMA
PRA Category 1 Credit™
Expiration date: December 7, 2008
- Molecular Pathogenesis of Non–Small-Cell Lung Cancer
- Individualizing Therapies in Non–Small-Cell Lung Cancer
Based on Tumor Biology and Patient Characteristics
- Optimizing the Use of EGFR Inhibitors in Patients With
Non–Small-Cell Lung Cancer
- Integration of Antiangiogenic Agents Into Treatment Paradigms
for Non–Small-Cell Lung Cancer
- Quality of Life and Adverse Events Associated With Targeted
Therapy in Non–Small-Cell Lung Cancer
- New Therapeutic Agents for Non–Small-Cell Lung Cancer
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2008
- Targeting Signaling Pathways to Inhibit Cancer Growth
- Targeting the MAP/MEK and PI3K/Akt Pathways
- Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer
- Vaccines in Lung Cancer
- Novel Immunologic Targets in Metastatic Melanoma
- Combining Targeted Agents to Improve Therapeutic Efficacy
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2008
- Combining VEGF and EGFR Inhibition in NSCLC
- Second-Generation Inhibitors of the VEGFR Tyrosine Kinase
- Small-Molecule TKIs in the Treatment of Advanced Thyroid Cancer
- Harnessing SPARC Protein for Uptake of Chemotherapy in Tumors
- Current Data on Raf/MEK Inhibitors in Melanoma and Other Cancers
- Understanding the Kinome and Its Role in Cancer Pathogenesis
|
|
